Appendix 4C & Quarterly Activities Report - March 2023
Filed with ASX · · 9 pages · English
Melbourne, Australia, 27 April 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a globalleaderinguideline‐drivengenomics‐basedtestinginhealth,wellnessandseriousdiseases,releasesitsAppendix 4CandQuarterlybusinessupdateforthequarterending31March2023(Q3FY23). Highlights: Announced the development of the world’s first CustomerCashReceipts(A$'000) Comprehensive Breast& Ova
Genetic Technologies Limited on 6ix
Story so far
Earlier from Genetic Technologies
- Publication Validates geneType Prostate Cancer Risk Test
- GeneType MultiTest Panel Expanded Inclusion of New Diseases
- Further Study Validates geneType Breast Cancer Risk Test
- Appendix 4D & Half-year Financial Report December 2022
- Receipt of R&D Tax Incentive Refund for geneType Multi Test
Later from Genetic Technologies
- Publication Validates geneType for Melanoma Risk Assessment
- Appendix 4C and Quarterly Activities Report - June 2023
- Updated Investor Presentation - August 2023
- 2023 Annual Report and Appendix 4E
- Annual Results Momentum Building on our Commercial Plans
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies